Profound Medical (PROF), Siemens Unite to Treat Prostate Cancer

01.03.24 17:58 Uhr

Werte in diesem Artikel
Aktien

172,30 EUR -1,80 EUR -1,03%

Indizes

PKT PKT

1.526,1 PKT -10,3 PKT -0,67%

17.730,3 PKT -107,1 PKT -0,60%

6.969,9 PKT -44,5 PKT -0,63%

2.975,3 PKT 0,8 PKT 0,03%

2.143,9 PKT 0,6 PKT 0,03%

189,6 PKT -0,9 PKT -0,47%

504,3 PKT -2,0 PKT -0,40%

4.918,3 PKT -18,3 PKT -0,37%

1.049,0 PKT -9,2 PKT -0,87%

9.457,2 PKT -61,4 PKT -0,65%

43.676,6 PKT 240,1 PKT 0,55%

17.734,5 PKT -14,5 PKT -0,08%

17.616,9 PKT -148,8 PKT -0,84%

6.966,4 PKT -40,6 PKT -0,58%

6.981,7 PKT -46,5 PKT -0,66%

13.439,9 PKT 30,7 PKT 0,23%

4.326,4 PKT -8,8 PKT -0,20%

17.673,2 PKT -84,8 PKT -0,48%

Profound Medical PROF announced its non-exclusive collaboration with Siemens Healthineers to set the stage for PROF to start marketing a full therapeutic solution.The partnership is intended to combine Profound Medical’s TULSA-PRO system with the Siemens Magnetom Free.Max magnetic resonance (MR) scanner. PROF's sales force is responsible for this combination. The business also intends to sell TULSA-PRO as a stand-alone offering. Customers can now employ the technology with the MR hardware of their choice.Price PerformanceFor the past six months, PROF shares have gained 1.8% compared with the industry’s growth of 2.6%. The S&P 500 rose 11.6% in the same time frame. Image Source: Zacks Investment Research More on the NewsThe transurethral ultrasound ablation procedure is carried out by TULSA-PRO. It uses sound absorption technology to kill targeted prostate tissue, while utilizing real-time magnetic resonance guidance for accuracy.Surgeons can use this technique to ablate prostate tissue, either whole or partial, in patients with low, intermediate, or high-risk prostate cancer. Benign prostatic hyperplasia (BPH) is also treated with it. Patients with prostate cancer, who are under active surveillance, and looking for cancer treatment and BPH symptom relief, can be treated with it.Magnetom Free.Max offers the built-in advantages of a mid-field MR scanner, while expanding the scope of MR clinical applications. To improve the patient experience, it makes MR scanning easier for larger or more claustrophobic individuals.The companies expect to bring their integrated offering to the market in 2025.Industry ProspectsPer a report by Grand View Research, the global prostate cancer therapeutics market size was valued at $12.1 billion in 2022, and is expected to grow 8.4% from 2023 to 2030.The market is witnessing growth due to factors like the increasing prevalence of prostate cancer, the adoption of novel screening and diagnostic technologies, and government support for new therapies to cure prostate cancer. The adoption of novel screening and diagnostic technologies is projected to promote the adoption of therapeutics.With the given market potential for treating prostate cancer, Profound Medical’s collaboration with Siemens is likely to boost its business and generate additional revenues.Profound Medical Price  Profound Medical price | Profound Medical QuoteZacks Rank & Stocks to ConsiderPROF carries a Zacks Rank #3 (Hold) at present.Some better-ranked stocks in the broader medical space that have announced quarterly results are Cencora, Inc. COR, Elevance Health, Inc. ELV and Cardinal Health, Inc. CAH.Cencora, carrying a Zacks Rank of 2 (Buy), reported first-quarter fiscal 2024 adjusted EPS of $3.28, beating the Zacks Consensus Estimate by 14.7%. Revenues of $72.25 billion outpaced the consensus mark by 5%. You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.Cencora has a long-term estimated growth rate of 8.6%. COR’s earnings surpassed estimates in the trailing four quarters, the average surprise being 6.7%.Elevance Health reported the fourth-quarter 2023 adjusted EPS of $5.62, beating the Zacks Consensus Estimate by 1.3%. Revenues of $42.45 billion outpaced the consensus mark by 1.5%. The company currently carries a Zacks Rank #2.Elevance Health has a long-term estimated growth rate of 12%. ELV’s earnings surpassed estimates in the trailing four quarters, the average surprise being 3.1%.Cardinal Health reported the second-quarter fiscal 2024 adjusted EPS of $1.82, beating the Zacks Consensus Estimate by 16.7%. Revenues of $57.45 billion surpassed the Zacks Consensus Estimate by 1.1%. The company currently carries a Zacks Rank #2.Cardinal Health has a long-term estimated growth rate of 15.9%. CAH’s earnings surpassed estimates in all the trailing four quarters, the average surprise being 15.6%.Zacks Names "Single Best Pick to Double" From thousands of stocks, 5 Zacks experts each have chosen their favorite to skyrocket +100% or more in months to come. From those 5, Director of Research Sheraz Mian hand-picks one to have the most explosive upside of all.It’s a little-known chemical company that’s up 65% over last year, yet still dirt cheap. With unrelenting demand, soaring 2022 earnings estimates, and $1.5 billion for repurchasing shares, retail investors could jump in at any time.This company could rival or surpass other recent Zacks’ Stocks Set to Double like Boston Beer Company which shot up +143.0% in little more than 9 months and NVIDIA which boomed +175.9% in one year.Free: See Our Top Stock and 4 Runners Up >>Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report Cardinal Health, Inc. (CAH): Free Stock Analysis Report Cencora, Inc. (COR): Free Stock Analysis Report Profound Medical (PROF): Free Stock Analysis Report Elevance Health, Inc. (ELV): Free Stock Analysis ReportTo read this article on Zacks.com click here.Zacks Investment ResearchWeiter zum vollständigen Artikel bei Zacks

Ausgewählte Hebelprodukte auf Profound Medical

Mit Knock-outs können spekulative Anleger überproportional an Kursbewegungen partizipieren. Wählen Sie einfach den gewünschten Hebel und wir zeigen Ihnen passende Open-End Produkte auf Profound Medical

NameHebelKOEmittent
NameHebelKOEmittent
Werbung

Quelle: Zacks

Nachrichten zu Siemens AG

Analysen zu Siemens AG

DatumRatingAnalyst
17.04.2024Siemens BuyJefferies & Company Inc.
15.04.2024Siemens OutperformRBC Capital Markets
12.04.2024Siemens BuyUBS AG
10.04.2024Siemens OutperformBernstein Research
08.04.2024Siemens OutperformRBC Capital Markets
DatumRatingAnalyst
17.04.2024Siemens BuyJefferies & Company Inc.
15.04.2024Siemens OutperformRBC Capital Markets
12.04.2024Siemens BuyUBS AG
10.04.2024Siemens OutperformBernstein Research
08.04.2024Siemens OutperformRBC Capital Markets
DatumRatingAnalyst
10.08.2023Siemens Market-PerformBernstein Research
10.08.2023Siemens HoldJoh. Berenberg, Gossler & Co. KG (Berenberg Bank)
07.07.2023Siemens HoldJoh. Berenberg, Gossler & Co. KG (Berenberg Bank)
29.06.2023Siemens Market-PerformBernstein Research
20.06.2023Siemens Market-PerformBernstein Research
DatumRatingAnalyst
05.04.2024Siemens UnderweightBarclays Capital
14.02.2024Siemens UnderweightBarclays Capital
09.02.2024Siemens UnderweightBarclays Capital
03.01.2024Siemens UnderweightBarclays Capital
20.11.2023Siemens UnderweightBarclays Capital

Um die Übersicht zu verbessern, haben Sie die Möglichkeit, die Analysen für Siemens AG nach folgenden Kriterien zu filtern.

Alle: Alle Empfehlungen

Buy: Kaufempfehlungen wie z.B. "kaufen" oder "buy"
Hold: Halten-Empfehlungen wie z.B. "halten" oder "neutral"
Sell: Verkaufsempfehlungn wie z.B. "verkaufen" oder "reduce"